| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Financial Officer
2 companies
David Arkowitz is Chief Financial Officer at MCRB, with reported holdings spanning 2 companies. David Arkowitz's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $373K at current prices.
Our model assigns David Arkowitz a middling insider score of 61/100, based on 3 past trades. Over a 12-month horizon, all 3 of those trades were profitable, with an average 12-month return of +24.5%.
David Arkowitz's largest disclosed position is in MCRB as Chief Financial Officer, worth about $358K. The MCRB filings lean toward selling, a net 8,005 shares.
David Arkowitz has 12 Form 4 filings on record from June 2021 to October 2026, across 2 companies: Director at iBio (IBIO), 2024–2026; Chief Financial Officer at Seres Therapeutics (MCRB), 2021–2024.
The 21 reported transactions were 12 option or other derivative awards, 3 option exercises, 3 stock awards and 2 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $50K and 2 sales worth about $10K.
The only open-market purchase was 18,382 shares of IBIO at an average $2.72 on January 10, 2025, about $50K. Twelve months later IBIO was up 6%.
The largest open-market sale was 4,066 shares of MCRB at an average $1.35 on October 30, 2023, about $5K. Twelve months later MCRB was down 47%.
Both sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 10, 2025 | IBIO Ibio, Inc. | Director | Buy | 18,382 | $2.72 | $49,999.04 | New | -52.5% | +5.9% | |
| Feb 16, 2024 | MCRB Seres Therapeutics, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 3,939 | $1.08 | $4,254.12 | -2.1% | -12.0% | -20.7% | |
| Oct 30, 2023 | MCRB Seres Therapeutics, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 4,066 | $1.35 | $5,489.10 | -2.3% | -13.8% | -46.8% |